| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032829822 |
| P356 | DOI | 10.1186/1472-6750-3-15 |
| P932 | PMC publication ID | 222906 |
| P698 | PubMed publication ID | 13129437 |
| P5875 | ResearchGate publication ID | 10413320 |
| P50 | author | Lennart Hammarström | Q5786999 |
| Susanna Ricci | Q56721689 | ||
| Gianni Pozzi | Q56721702 | ||
| Donata Medaglini | Q56839963 | ||
| Paola Bossù | Q60043687 | ||
| P2093 | author name string | Tiziana Maggi | |
| Li Xu | |||
| Diana Boraschi | |||
| Paolo Ruggiero | |||
| Aldo Tagliabue | |||
| Giovanni Macchia | |||
| P2860 | cites work | Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting | Q24318910 |
| Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 | Q28179431 | ||
| Interleukin-1 receptor antagonist: role in biology | Q28271409 | ||
| Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene | Q28593669 | ||
| Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis | Q30304298 | ||
| Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. | Q30453928 | ||
| Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification | Q31972219 | ||
| Potential treatment of osteoarthritis by gene therapy | Q33651413 | ||
| Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine | Q33756245 | ||
| Probiotics and inflammatory bowel diseases | Q33816844 | ||
| Proinflammatory cytokines | Q33913139 | ||
| Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii. | Q34003291 | ||
| Gene therapy of chronic inflammatory disease | Q34079566 | ||
| Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics | Q34141280 | ||
| Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis | Q34236293 | ||
| Interleukin-1 receptor antagonist gene therapy for arthritis | Q34442700 | ||
| Immunotherapeutic approaches to inflammatory bowel diseases | Q34451989 | ||
| Influence of interleukin-1 receptor antagonist gene polymorphism on disease | Q34461355 | ||
| Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice | Q37306765 | ||
| Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. | Q39741884 | ||
| Human interleukin-1 receptor antagonist: large-scale expression in Bacillus brevis 47-5Q. | Q40915995 | ||
| Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II. | Q41115990 | ||
| Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance | Q41126096 | ||
| Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. | Q41267810 | ||
| Binding of IL-1 beta to IL-1R type II at single cell level | Q41667053 | ||
| Cytokines in inflammatory bowel disease | Q41730146 | ||
| Vaginal immunization with recombinant gram-positive bacteria. | Q41731866 | ||
| Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation | Q42258741 | ||
| A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbits | Q43740171 | ||
| The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. | Q44854412 | ||
| Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro | Q45862217 | ||
| Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury | Q45881303 | ||
| Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. | Q45881466 | ||
| In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy | Q45882179 | ||
| Treatment of rheumatoid arthritis with IL-1 inhibitors | Q45890242 | ||
| Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation | Q46516903 | ||
| Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice | Q46812863 | ||
| Inflammatory bowel disease: etiology and pathogenesis | Q47899867 | ||
| Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). | Q47901523 | ||
| Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist | Q47912627 | ||
| Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 | ||
| Genetic engineering of Streptococcus gordonii for the simultaneous display of two heterologous proteins at the bacterial surface. | Q54545165 | ||
| Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like domains | Q57988358 | ||
| Interleukin-1 receptor antagonist reduces mortality from endotoxin shock | Q59092106 | ||
| Method and parameters for genetic transformation of Streptococcus sanguis challis | Q60920185 | ||
| Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice | Q61454672 | ||
| A host-vector system for heterologous gene expression in Streptococcus gordonii | Q62671433 | ||
| The international standards for interleukin-1 alpha and interleukin-1 beta. Evaluation in an international collaborative study | Q68012009 | ||
| Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis | Q71503443 | ||
| Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression | Q71548098 | ||
| Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist | Q72271510 | ||
| Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group | Q72472826 | ||
| Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria | Q73035266 | ||
| In situ delivery of passive immunity by lactobacilli producing single-chain antibodies | Q74381949 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukins | Q194908 |
| Streptococcus gordonii | Q7623352 | ||
| P304 | page(s) | 15 | |
| P577 | publication date | 2003-09-17 | |
| P1433 | published in | BMC Biotechnology | Q15753225 |
| P1476 | title | In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii | |
| P478 | volume | 3 |
| Q37896455 | Bio-inspired, bioengineered and biomimetic drug delivery carriers |
| Q38806283 | Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects |
| Q40436195 | Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine |
| Q54440505 | Comparison of transformation protocols in Streptococcus gordonii and evaluation of native promoter strength using a multiple-copy plasmid. |
| Q36316890 | Delivery of therapeutic proteins to the mucosa using genetically modified microflora |
| Q49339110 | Engineering bacteria for diagnostic and therapeutic applications |
| Q34911427 | IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines |
| Q38116457 | IL-1Ra and its delivery strategies: inserting the association in perspective. |
| Q37258771 | Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. |
| Q24799750 | Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria |
| Q89493327 | Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives |
| Q92668932 | Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease |
Search more.